Logo for StageZero Life Sciences Ltd

StageZero Life Sciences Investor Relations Material

Latest events

Logo for StageZero Life Sciences Ltd

Q1 2024

StageZero Life Sciences
Logo for StageZero Life Sciences

Q1 2024

21 May, 2024
Logo for StageZero Life Sciences

Q3 2023

15 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from StageZero Life Sciences Ltd

Access all reports
StageZero Life Sciences Ltd. specializes in providing molecular diagnostic solutions, leveraging a telehealth program that employs advanced diagnostics for the early detection of cancer and chronic diseases. The company is known for developing blood-based biomarker tests, particularly for identifying colorectal cancer. A key innovation from StageZero is its Sentinel Principle technology, which is instrumental in early disease diagnosis, staging, response identification, and treatment monitoring. Additionally, StageZero offers Aristotle, an mRNA-based test capable of detecting multiple cancers from a single blood sample. StageZero Life Sciences is headquartered in Richmond Hill, Ontario, and its shares are listed on the Toronto Stock Exchange.